Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
1,472
datasets available to search
ShareScore release 0.9.0
Dataset results
1,472 results for “EGFR”
A Study to Assess the Incidence of EGFR Mutation in Patients With Newly Diagnosed Locally Advanced or Metastatic Non-Small Cell Lung Cancer in the UK, And of Tarceva (Erlotinib) as First-Line Therapy
ClinicalTrials.gov study NCT01250119. IPD Sharing: Not stated. Countries: 1. Publications: 0.
EGFR-TKIs Combine Chemotherapy as First-line Therapy for Patients With Advanced EGFR Mutation-positive NSCLC
ClinicalTrials.gov study NCT02886195. IPD Sharing: UNDECIDED. Countries: 0. Publications: 1.
A Study to Assess Biomarkers Impact on Participants Response to Erlotinib Treatment for First-line Non-Small Cell Lung Cancer With Endothelial Growth Factor Receptor (EGFR) Activating Mutations
ClinicalTrials.gov study NCT01153984. IPD Sharing: Not stated. Countries: 1. Publications: 0.
A Study of Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy Compared With Platinum-Based Chemotherapy in Patients With Epidermal Growth Factor Receptor (EGFR)-Mutated Locally
ClinicalTrials.gov study NCT04988295. IPD Sharing: YES. Countries: 29. Publications: 0.
A Study of EGF816 and Gefitinib in TKI-naïve EGFR-mutant Non-Small Cell Lung Cancer
ClinicalTrials.gov study NCT03292133. IPD Sharing: NO. Countries: 1. Publications: 0.
A Study on the Correlation Between Tarceva (Erlotinib) - Induced Rash and Efficacy in EGFR Mutated Participants With Advanced Non-Small Cell Lung Cancer Receiving First-Line Therapy
ClinicalTrials.gov study NCT01174563. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Atezolizumab and Bevacizumab in EGFR Mutant NSCLC in Patients With Progressive Disease After Receiving Osimertinib
ClinicalTrials.gov study NCT04099836. IPD Sharing: NO. Countries: 1. Publications: 0.
Phase II Trial of BIBW 2992 (Afatinib) in Genetically Pre-screened Cancers With EGFR and/or HER2 Gene Amplification.
ClinicalTrials.gov study NCT00748709. IPD Sharing: NO. Countries: 2. Publications: 0.
Erlotinib (Tarceva) as a Single Agent or Intercalated With Combination Chemotherapy in Patients With EGFR Positive NSCLC
ClinicalTrials.gov study NCT00294762. IPD Sharing: Not stated. Countries: 2. Publications: 0.
An Open Label, Multicenter, Phase II Study of Dacomitinib for EGFR Mutated Non-Small Cell Lung Cancer (NSCLC) With Brain Metastases
ClinicalTrials.gov study NCT04339829. IPD Sharing: Not stated. Countries: 0. Publications: 13.
A Molecular Profiling Study of Patients With EGFR Mutation-positive Locally Advanced or Metastatic NSCLC Treated With Osimertinib
ClinicalTrials.gov study NCT03239340. IPD Sharing: YES. Countries: 5. Publications: 0.
A Study Osimertinib in Patients With Stage 4 Non-small Cell Lung Cancer With Uncommon EGFR Mutations
ClinicalTrials.gov study NCT03434418. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Study to Assess AFM24 in Combination With Atezolizumab in Selected Advanced/Metastatic EGFR-expressing Cancers
ClinicalTrials.gov study NCT05109442. IPD Sharing: Not stated. Countries: 5. Publications: 0.
Study of Furmonertinib as Neoadjuvant Therapy for Resectable Stage Ⅱ-ⅢB EGFR Sensitive Mutant NSCLC
ClinicalTrials.gov study NCT05987826. IPD Sharing: Not stated. Countries: 0. Publications: 44.
A Phase II Study of Cetuximab Plus Irinotecan in Patients With EGFR-detectable Metastatic Colorectal Carcinoma
ClinicalTrials.gov study NCT00362102. IPD Sharing: Not stated. Countries: 0. Publications: 1.
Phase II Study of Erlotinib, an EGFR Inhibitor in Metastatic EGFR-positive 'Triple Receptor-negative' Breast Cancer
ClinicalTrials.gov study NCT00739063. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Kidney Damage In Patients With Severe Fall In eGFR
ClinicalTrials.gov study NCT01136915. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Dacomitinib for Treatment of Patients in India With Metastatic Non Small Cell Lung Cancer With EGFR Activating Mutations
ClinicalTrials.gov study NCT04511533. IPD Sharing: YES. Countries: 1. Publications: 0.
Erlotinib Re-Challenge for Recurrent EGFR-mutant Lung Cancer in Patients Who Previously Received Adjuvant Erlotinib or Gefitinib
ClinicalTrials.gov study NCT01189435. IPD Sharing: Not stated. Countries: 1. Publications: 0.
The Safety,Efficacy of Anti-EGFR Humanized Monoclonal Antibody Combined With Chemotherapy in Advanced Solid Tumors.
ClinicalTrials.gov study NCT03577704. IPD Sharing: Not stated. Countries: 1. Publications: 0.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.